This Kepivance market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the increasing use of hematopoietic stem cell transplantation, FDA approval, and clinical endorsement, enhanced awareness of mucositis management, rising investment in cancer supportive care, and advancements in healthcare systems.
Growth during the market's forecast period will be driven by the rising number of stem cell transplant procedures, advancements in cancer treatment protocols, improved healthcare access in emerging markets, government and regulatory support, and a greater focus on supportive cancer care. Key trends in the forecast period include market expansion in oncology applications, growth in emerging markets, a stronger emphasis on supportive cancer care, ongoing R&D for new indications, and continued technological advancements and innovations.
The increasing prevalence of cancer is expected to drive the growth of the kepivance market in the future. Cancer encompasses a range of diseases marked by the uncontrolled growth and spread of abnormal cells. The rising prevalence of cancer can be attributed to several factors, including an aging population, lifestyle choices such as poor diet and smoking, better diagnostic and screening methods, and improved survival rates due to advancements in cancer treatments. Kepivance, a medication used to treat mucositis caused by chemotherapy or radiation, helps relieve the painful symptoms of oral mucositis, improving patients' quality of life and enabling them to continue their cancer treatments. For example, in January 2024, the American Cancer Society reported that the number of cancer cases increased to 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting a growth of 2.19%. Therefore, the growing prevalence of cancer is driving the expansion of the kepivance market.
The expansion of healthcare infrastructure is expected to further accelerate the growth of the kepivance market. Healthcare infrastructure includes the physical facilities, organizational structures, and resources required to deliver healthcare services effectively. This expansion is driven by factors such as population growth, aging demographics, rising chronic diseases, and the need for more accessible healthcare. As healthcare infrastructure grows, it supports the administration of Kepivance by providing specialized facilities and trained professionals for its intravenous delivery and monitoring during cancer treatments. For instance, in September 2024, Cross River Therapy, a U.S.-based provider of ABA therapy services, published statistics showing that the U.S. pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medicine in 2021. Spending is projected to rise to $605-$635 billion by 2025. Therefore, the expansion of healthcare infrastructure is fueling the growth of the kepivance market.
The increasing focus on personalized medicine is also expected to enhance the growth of the kepivance market. Personalized medicine tailors treatment and healthcare strategies to individual patients based on their specific characteristics, needs, and genetic profiles. The growing demand for personalized medicine is driven by advancements in genomics, targeted therapies, and the rising prevalence of chronic diseases, all of which require more precise treatment methods. Personalized medicine improves the use of Kepivance (palifermin) by customizing its administration for patients undergoing high-dose chemotherapy and stem cell transplants, optimizing protection against oral mucositis according to individual risk factors. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to six in 2022. This included seven cancer drugs and three treatments for other conditions. Therefore, the growing focus on personalized medicine is contributing to the expansion of the kepivance market.
The key company operating in the kepivance market is Biovitrum AB.
North America was the largest region in the kepivance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kepivance report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Kepivance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) designed to stimulate the growth of epithelial cells. It is primarily used to reduce the occurrence and severity of oral mucositis in patients undergoing myelotoxic cancer therapies, such as hematopoietic stem cell transplantation. By promoting the repair and regeneration of the oral mucosa, Kepivance helps alleviate pain and improve the quality of life during treatment.
The primary indications for kepivance are the prevention and treatment of oral mucositis, a painful condition often caused by chemotherapy or radiation therapy. The formulations include injectable preparations and lyophilized powders for reconstitution, with administration routes being intramuscular and subcutaneous injections. Distribution channels for Kepivance include direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies. It is used by various healthcare providers, including hospitals, oncology clinics, hematology treatment centers, and home healthcare services.
The kepivance market research report is one of a series of new reports that provides kepivance market statistics, including kepivance industry global market size, regional shares, competitors with a kepivance market share, detailed kepivance market segments, market trends and opportunities, and any further data you may need to thrive in the kepivance industry. This kepivance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The kepivance market consists of sales of palifermin-based therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the increasing use of hematopoietic stem cell transplantation, FDA approval, and clinical endorsement, enhanced awareness of mucositis management, rising investment in cancer supportive care, and advancements in healthcare systems.
Growth during the market's forecast period will be driven by the rising number of stem cell transplant procedures, advancements in cancer treatment protocols, improved healthcare access in emerging markets, government and regulatory support, and a greater focus on supportive cancer care. Key trends in the forecast period include market expansion in oncology applications, growth in emerging markets, a stronger emphasis on supportive cancer care, ongoing R&D for new indications, and continued technological advancements and innovations.
The increasing prevalence of cancer is expected to drive the growth of the kepivance market in the future. Cancer encompasses a range of diseases marked by the uncontrolled growth and spread of abnormal cells. The rising prevalence of cancer can be attributed to several factors, including an aging population, lifestyle choices such as poor diet and smoking, better diagnostic and screening methods, and improved survival rates due to advancements in cancer treatments. Kepivance, a medication used to treat mucositis caused by chemotherapy or radiation, helps relieve the painful symptoms of oral mucositis, improving patients' quality of life and enabling them to continue their cancer treatments. For example, in January 2024, the American Cancer Society reported that the number of cancer cases increased to 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting a growth of 2.19%. Therefore, the growing prevalence of cancer is driving the expansion of the kepivance market.
The expansion of healthcare infrastructure is expected to further accelerate the growth of the kepivance market. Healthcare infrastructure includes the physical facilities, organizational structures, and resources required to deliver healthcare services effectively. This expansion is driven by factors such as population growth, aging demographics, rising chronic diseases, and the need for more accessible healthcare. As healthcare infrastructure grows, it supports the administration of Kepivance by providing specialized facilities and trained professionals for its intravenous delivery and monitoring during cancer treatments. For instance, in September 2024, Cross River Therapy, a U.S.-based provider of ABA therapy services, published statistics showing that the U.S. pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medicine in 2021. Spending is projected to rise to $605-$635 billion by 2025. Therefore, the expansion of healthcare infrastructure is fueling the growth of the kepivance market.
The increasing focus on personalized medicine is also expected to enhance the growth of the kepivance market. Personalized medicine tailors treatment and healthcare strategies to individual patients based on their specific characteristics, needs, and genetic profiles. The growing demand for personalized medicine is driven by advancements in genomics, targeted therapies, and the rising prevalence of chronic diseases, all of which require more precise treatment methods. Personalized medicine improves the use of Kepivance (palifermin) by customizing its administration for patients undergoing high-dose chemotherapy and stem cell transplants, optimizing protection against oral mucositis according to individual risk factors. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to six in 2022. This included seven cancer drugs and three treatments for other conditions. Therefore, the growing focus on personalized medicine is contributing to the expansion of the kepivance market.
The key company operating in the kepivance market is Biovitrum AB.
North America was the largest region in the kepivance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kepivance report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Kepivance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) designed to stimulate the growth of epithelial cells. It is primarily used to reduce the occurrence and severity of oral mucositis in patients undergoing myelotoxic cancer therapies, such as hematopoietic stem cell transplantation. By promoting the repair and regeneration of the oral mucosa, Kepivance helps alleviate pain and improve the quality of life during treatment.
The primary indications for kepivance are the prevention and treatment of oral mucositis, a painful condition often caused by chemotherapy or radiation therapy. The formulations include injectable preparations and lyophilized powders for reconstitution, with administration routes being intramuscular and subcutaneous injections. Distribution channels for Kepivance include direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies. It is used by various healthcare providers, including hospitals, oncology clinics, hematology treatment centers, and home healthcare services.
The kepivance market research report is one of a series of new reports that provides kepivance market statistics, including kepivance industry global market size, regional shares, competitors with a kepivance market share, detailed kepivance market segments, market trends and opportunities, and any further data you may need to thrive in the kepivance industry. This kepivance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The kepivance market consists of sales of palifermin-based therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Kepivance Market Characteristics4. Kepivance Market Trends and Strategies5. Kepivance Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Kepivance Pricing Analysis & Forecasts30. Global Kepivance Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Kepivance Market32. Recent Developments in the Kepivance Market
3. Kepivance Market Biologic Drug Characteristics
6. Global Kepivance Growth Analysis and Strategic Analysis Framework
8. Kepivance Market Segmentation
9. Global Kepivance Epidemiology of Clinical Indications
10. Kepivance Market Regional and Country Analysis
11. Asia-Pacific Kepivance Market
12. China Kepivance Market
13. India Kepivance Market
14. Japan Kepivance Market
15. Australia Kepivance Market
16. South Korea Kepivance Market
17. Western Europe Kepivance Market
18. UK Kepivance Market
19. Germany Kepivance Market
20. France Kepivance Market
21. Eastern Europe Kepivance Market
22. North America Kepivance Market
23. USA Kepivance Market
24. Canada Kepivance Market
25. South America Kepivance Market
26. Middle East Kepivance Market
27. Africa Kepivance Market
28. Kepivance Market Competitive Landscape and Company Profiles
29. Global Kepivance Market Pipeline Analysis
33. Kepivance Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Kepivance Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on kepivance market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for kepivance? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kepivance market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Prevention of Oral Mucositis; Treatment of Oral Mucositis2) by Formulation: Injectable Formulation; Lyophilized Powder For Reconstitution
3) by Route of Administration: Intramuscular Injection; Subcutaneous Injection
4) by Distribution Channel: Direct Sales; Wholesalers and Distributor; Retail Pharmacies; Online Pharmacies
5) by End-User: Hospitals; Oncology Clinics; Hematology Treatment Centers; Home Healthcare Providers
Key Companies Mentioned: Biovitrum AB
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Biovitrum AB
